rosiglitazone has been researched along with Hormone-Dependent Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lyles, BE; Moss, PE; Stewart, LV | 1 |
| Abdel-Mageed, AB; Akingbemi, B; Bartol, F; Braden, T; Dennis, J; Hazi, A; Judd, R; Mansour, M; Morrison, E; Napier, I; Schwartz, D | 1 |
2 other study(ies) available for rosiglitazone and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
The PPARĪ³ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.
Topics: Androgen-Binding Protein; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dihydrotestosterone; Gene Expression; Genes, Reporter; Humans; Hypoglycemic Agents; Male; Mutation; Neoplasms, Hormone-Dependent; PPAR gamma; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Transfection | 2010 |
Thiazolidinediones/PPARĪ³ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Survival; Chromans; Enzyme-Linked Immunosorbent Assay; Fatty Acid Synthase, Type I; Humans; Hypoglycemic Agents; Male; Neoplasms, Hormone-Dependent; PPAR gamma; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Vasodilator Agents | 2011 |